HPV is the main cause of cervical cancer, and current therapeutic vaccines primarily target the E6 and E7 proteins produced by tumor cells to induce specific immune responses.
Researchers developed a dendritic cell (DC) vaccine using a modified adenovirus to express the E6/E7 fusion gene from HPV-16, enhancing the vaccine's ability to stimulate cytotoxic T lymphocytes (CTL).
The study demonstrated that this DC vaccine significantly increased the apoptosis and killing rate of cervical cancer cells (CaSki) by specific CTLs, indicating its potential as a new treatment strategy for cervical cancer.